DMYD-B.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:29):

Stats
Dzisiejszy wolumen	76 851.00
Średni wolumen	273 381
Kapitalizacja rynkowa	1.03B
EPS	SEK0 ( 2023-10-11 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-8.21
ATR14	SEK0.0550 (0.49%)

Wolumen Korelacja

Długi: 0.23 (neutral)

Krótki: 0.00 (neutral)

Signal:(63.628) Neutral

Diamyd Medical AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Diamyd Medical AB (publ) Korelacja - Waluta/Towar

-0.13
( neutral )

-0.44
( neutral )

0.00
( neutral )

0.10
( neutral )

0.58
( weak )

Diamyd Medical AB (publ) Finanse

Annual	2023
Przychody:	SEK546 000
Zysk brutto:	SEK-3.09M (-565.57 %)
EPS:	SEK-1.480

FY	2023
Przychody:	SEK546 000
Zysk brutto:	SEK-3.09M (-565.57 %)
EPS:	SEK-1.480

FY	2022
Przychody:	SEK454 000
Zysk brutto:	SEK-3.95M (-869.82 %)
EPS:	SEK-1.130

FY	2021
Przychody:	SEK253 000
Zysk brutto:	SEK-2.25M (-888.54 %)
EPS:	SEK0.868

Financial Reports:

No articles found.

Diamyd Medical AB (publ)

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.